Frazier Life Sciences is a venture capital and public equity investment firm focused on biopharmaceuticals, partnering with and building companies developing novel therapeutics from company creation through public markets. The firm closed its latest venture fund at $1.3 billion in 2025.
55% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $125.0M (across 54 rounds with reported amounts).
Portfolio
52
Fund Size
$1.3B
Top Stage
Series A
Last 12 Mo
14
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
56 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
 RQ Bio | Series A | $115M | Jun 2026 |
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
 Immutrin | Series A | $87M | Mar 2026 |
 Vima Therapeutics | Series A | $40M | Mar 2026 |
| VVima | Series A | $100M | Mar 2026 |
| SSidewinder Therapeutics | Series B | $137M | Jan 2026 |
 Sidewinder | Series B | $137M | Jan 2026 |
| RRq Biotechnology Ltd | Series A | $115M | Jan 2026 |
 Iolyx Therapeutics | Series B | $15M | Dec 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Braveheart | Series A | $185M | Nov 2025 |
| BBraveheart Bio | Series A | $185M | Nov 2025 |
 Tubulis | Series C | — | Oct 2025 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Hillstar Bio | Series A | $67M | Mar 2025 |
 Callio Therapeutics | Series A | $187M | Mar 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
 Alesta Therapeutics | Series A | — | Jan 2025 |
| SStar Tx | Series D | $125M | Jan 2025 |
| HHillstar | Series A | $67M | Jan 2025 |
 35 Pharma | Series C | $53M | Nov 2024 |
 Alentis Therapeutics | Series D | $181.4M | Nov 2024 |
| AAlentis | Series D | $181.4M | Nov 2024 |
 Alpha-9 Oncology | Series C | $175M | Oct 2024 |
Page 1 of 3
Top Co-Investors
Frazier Healthcare Partners23 shared
RA Capital Management18 shared
OrbiMed16 shared
Wellington Management13 shared
Deep Track Capital13 shared
Longitude Capital8 shared
Samsara BioCapital8 shared
Logos Capital8 shared
Norwest Venture Partners7 shared
Alexandria Venture Investments6 shared
Forbion5 shared
Enavate Sciences5 shared
Cormorant Asset Management5 shared
New Enterprise Associates5 shared
BVF Partners L.P.4 shared
Nextech Invest Ltd.4 shared
Lightspeed Venture Partners4 shared
Soleus Capital4 shared
LifeArc Ventures4 shared
Last updated: 7 September 2026